The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
Official Title: An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma
Study ID: NCT00189306
Brief Summary: An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.
Detailed Description: Evaluate the long-term sustained clearance rate, defined as the proportion of those subjects clinically clear of basal cell carcinoma (BCC) at the treated superficial BCC (sBCC) target tumor site at the 12-week posttreatment visit who remain clear during a 5 year follow-up period.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Medical Centre, Concord Hospital, Concord, New South Wales, Australia
Prince of Wales Hospital, Randwick, New South Wales, Australia
Skin Centre, Benowa, Queensland, Australia
South East Dermatology Centre, Carina Heights, Queensland, Australia
105 Fulham Road, Gulliver, Queensland, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Flinders Medical Center, Bedford Park, South Australia, Australia
Queen Elizabeth Hospital, Woodville, South Australia, Australia
Western Hospital, Footscray, Victoria, Australia
Austin & Repartriation Hospital, Heidelburg, Victoria, Australia
Freemantle Dermatology, Fremantle, Western Australia, Australia
158 South Terrace, Perth, Western Australia, Australia
Subiaco Clinic, Subiaco, Western Australia, Australia
103A Mountain Road, Epsom, Auckland, New Zealand
Birthcare Building, Parnell, Auckland, New Zealand
Colombo Mansions, Christchurch, , New Zealand
Dermatology Practice, Christchurch, , New Zealand
Skin Institute Limited, Takapuna, , New Zealand
Name: Jim Lee, Dr.
Affiliation: Graceway Pharmaceuticals
Role: STUDY_DIRECTOR